Schedule 13G ownership disclosure

ALNYLAM PHARMACEUTICALS INC COM

Common Stock · CUSIP: 02043Q107

Event date: 2024-12-31

Filing-level shares
6,968,513.00
Percent of class
5.4%
  • Capital Research Global Investors

    Shares: 6,968,513.00 · Class: 5.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001422848-25-000022
Form type
SCHEDULE 13G
Filer
ALNYLAM PHARMACEUTICALS, INC.
CIK
CIK 1178670
Filed
Feb 13, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub